Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data

TARS Tarsus Pharmaceuticals

17.420
-0.420-2.35%
Close 10/05 16:00 ET
17.4200.0000.00%
Post Mkt Price 10/05 16:00 ET
High
17.800
Open
17.520
Turnover
765.59K
Low
17.070
Pre Close
17.840
Volume
43.76K
Market Cap
464.39M
P/E(TTM)
Loss
52wk High
31.000
Shares
26.66M
P/E(Static)
Loss
52wk Low
10.800
Float Cap
239.78M
Bid/Ask %
-33.33%
Historical High
63.690
Shs Float
13.76M
Volume Ratio
0.55
Historical Low
10.800
Dividend TTM
--
Div Yield TTM
--
P/B
2.10
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.32%
Amplitude
4.09%
Avg Price
17.495
Lot Size
1
Float Cap
239.78M
Bid/Ask %
-33.33%
Historical High
63.690
Shs Float
13.76M
Volume Ratio
0.55
Historical Low
10.800
Dividend TTM
--
P/B
2.10
Dividend LFY
--
Turnover Ratio
0.32%
Amplitude
4.09%
Avg Price
17.495
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
CEO: Dr. Bobak Azamian, M.D.,PhD
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...